Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism
Elizabeth de Fougerolles Nunn, Natasha Jaiswal, Matthew Gavin, et al.
Molecular Metabolism (2024) Vol. 80, pp. 101880-101880
Open Access | Times Cited: 23

Showing 23 citing articles:

Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?
Caterina Conte, Kevin D. Hall, Samuel Klein
JAMA (2024) Vol. 332, Iss. 1, pp. 9-9
Closed Access | Times Cited: 40
Changes in lean body mass with glucagon‐like peptide‐1‐based therapies and mitigation strategies
Ian J. Neeland, Jennifer Linge, Andreas L. Birkenfeld
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S4, pp. 16-27
Closed Access | Times Cited: 34
Muscle-derived myostatin is a major endocrine driver of follicle-stimulating hormone synthesis
Luisina Ongaro, Xiang Zhou, Ying Wáng, et al.
Science (2025) Vol. 387, Iss. 6731, pp. 329-336
Closed Access | Times Cited: 2
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 14
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
Konstantinos Stefanakis, Michail Kokkorakis, Christos S. Mantzoros
Metabolism (2024), pp. 156057-156057
Closed Access | Times Cited: 10
Geroscience in heart failure: the search for therapeutic targets in the shared pathobiology of human aging and heart failure
Claire Castro, Constance Delwarde, Yanxi Shi, et al.
The Journal of Cardiovascular Aging (2025) Vol. 5, Iss. 1
Open Access
Balancing fat loss and muscle loss in the quest to reduce obesity in patients with heart failure
Sheldon E. Litwin
Journal of Cardiac Failure (2025)
Closed Access
Clinical Data Mega-Collection of Obesity and Obesity-Related Trials: Primary Inclusion Criteria from All Studies and Highlights of Clinical Efficacy Analysis of GLP-1 Drugs
Trung Tin Nguyen, David R. Elmaleh
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 812-812
Open Access
Optimised Skeletal Muscle Mass as a Key Strategy for Obesity Management
Thomas M. Barber, Stefan Kabisch, A. Pfeiffer, et al.
Metabolites (2025) Vol. 15, Iss. 2, pp. 85-85
Open Access
Advances in Oral Biomacromolecule Therapies for Metabolic Diseases
Qiuxia Jiao, Yuan Huang, Jinhan He, et al.
Pharmaceutics (2025) Vol. 17, Iss. 2, pp. 238-238
Open Access
Skeletal muscle growth to combat diabetes and obesity: the potential role of muscle‐secreted factors
Mitchell J. Sammut, Benjamin R. Thorne, C.W. James Melling
Obesity (2025)
Open Access
Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults
Marco Infante, F Silvestri, Nathalia Padilla, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1303-1303
Open Access
Combating chronic kidney disease-associated cachexia: A literature review of recent therapeutic approaches
Yalda Rahbar Saadat, Amin Abbasi, Seyyed Sina Hejazian, et al.
BMC Nephrology (2025) Vol. 26, Iss. 1
Open Access
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Allison B. Reiss, Shelly Gulkarov, Raymond Lau, et al.
Biomolecules (2025) Vol. 15, Iss. 3, pp. 408-408
Open Access
The role of incretin receptor agonists in the treatment of obesity
Thomas Först, Christophe De Block, Stefano Del Prato, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4178-4196
Open Access | Times Cited: 3
Impact of Selected Glucagon-like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism—A Narrative Review
Zsolt Szekeres, András Nagy, K. Jahner, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8214-8214
Open Access | Times Cited: 3
Cellular Senescence and Extracellular Vesicles in the Pathogenesis and Treatment of Obesity—A Narrative Review
Yicong Liang, Devesh Kaushal, Robert Wilson
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7943-7943
Open Access | Times Cited: 2
Why are we still in need for novel anti-obesity medications?
Aaron Novikoff, Gerald Grandl, Xue Liu, et al.
The Lancet Regional Health - Europe (2024) Vol. 47, pp. 101098-101098
Closed Access | Times Cited: 2
Obesity management strategies should cut fat, not muscle
Daan Kremer, Dionne Sizoo, Stephan J. L. Bakker, et al.
International Journal of Obesity (2024) Vol. 48, Iss. 7, pp. 1039-1040
Closed Access | Times Cited: 1
INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-γ signaling
Fanglin Li, Long-hua Gu, Yong-liang Tong, et al.
Acta Pharmacologica Sinica (2024)
Closed Access | Times Cited: 1
Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity
Manmeet Kaur, Saurav Misra
Journal of Basic and Clinical Physiology and Pharmacology (2024)
Closed Access | Times Cited: 1
Treatment of hypothalamic obesity with GLP-1 analogs
Paul Dimitri, Christian L. Roth
Journal of the Endocrine Society (2024) Vol. 9, Iss. 1
Open Access
Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle
Ran Hee Choi, Takuya Karasawa, Cesar Meza, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1

Scroll to top